Citi says Hutchmed-GSK deal validates platform pre-clinical
Citi analysts say Hutchmed’s licensing deal with GSK appears to validate the company’s drug candidate platform ahead of clinical trials. The deal could be worth up to US$1.295 billion, excluding additional components.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.